A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women

Inclusion Criteria: * Postmenopausal women with body mass index \>/= 18 and \</= 38 kg/m2 * Normal cervix and vagina * An intact uterus * An acceptable results from an endometrial biopsy * normal mammogram report within 24 months of screening Exclusion Criteria: Prior abnormal cervical screening test (CST) or Pap result within 2 years of screening. Subject can have atypical squamous cells of undetermined significance (ASCUS), if HPV negative. Subjects with any self-reported active sexually transmitted disease and/or evidence of infection based on visual vaginal exam by the investigator Subjects with a UTI during screening as assessed by urine dipstick test with abnormal test findings (any positive result for leukocytes AND any positive result for nitrites) Subjects with \> 4 mm endometrium lining at screening (on the transvaginal ultrasound) Have a history of endometrial hyperplasia or cervical or uterine carcinoma Subjects with indwelling catheters or requiring intermittent catheterization Subjects with multiple or unsuccessful (e.g., still having symptoms) pelvic reconstructive surgery, or suffers from pelvic relaxation Subjects who have had a hysterectomy Subjects taking any estrogen and/or progesterone products (see Section 4.1 for washout requirements) Subjects with concomitant use of personal lubricants (water-based lubricants are allowed) or any intravaginal product or medication, either by prescription or over-the-counter (e.g., Femring \[estradiol acetate…